IRLAB Provides Additional Efficacy Data from the Phase IIb Study of Pirepemat in Patients with Parkinson's Disease

GOTHENBURG, SE / ACCESS Newswire / March 28, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, March 28, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for …
Jetzt den vollständigen Artikel lesen